All Articles
Genmab offers patient support services through its MyNavCare program to assist patients who receive Epkinly and through its Seagen Secure patient assistance program for patients who receive Tivdak. Read More ›
The Geron REACH4RYTELO Patient Support Program can help your eligible patients who have
been prescribed Rytelo navigate access and affordability. Read More ›
SpringWorks CareConnections provides personalized support services and resources to help
patients start and stay on track with their SpringWorks medications. Read More ›
The fight for dominance over healthcare delivery, resources, and decision-making
intensifies as private equity, AI, and corporate consolidation reshape the
landscape. Read More ›
By Denise Danos, PhD; Eileen Mederos, RN; Dina Brackman, RN; Jennifer Gex, RN; Pamela Tuli, MD; Jennifer Manning, DNS, ACNS-BC, CNE; Alison Davis, PhD, RN, CNE, CHSE; Augusto Ochoa, MD
Discover how virtual research nurses are transforming clinical trials in community
oncology, making research more accessible and efficient. Read More ›
Hazardous drug exposure remains a critical challenge, requiring rigorous safety
protocols and a culture of vigilance in healthcare settings. Read More ›
On November 6, 2025, the FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with high-risk smoldering multiple myeloma (SMM). Darzalex Faspro is only indicated for patients with high-risk SMM. It is not indicated for other risk categories. Read More ›
On October 23, 2025, the FDA approved belantamab mafodotin-blmf (Blenrep) in combination with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma. This approval applies to patients who have received at least 2 prior therapies, including a proteasome inhibitor and an intermodulary agent. Read More ›
On October 24, 2025, the FDA approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 years and older with relapsed or refractory acute myeloid leukemia (AML) characterized by a susceptible nucleophosmin 1 (NPM1) mutation with no satisfactory alternative treatment options. Read More ›
Learn how revamped oncology navigation programs improve patient outcomes and
streamline care delivery in cancer treatment. Read More ›